SYS-CON MEDIA Authors: Michael Bushong, PR.com Newswire, David Smith, Tim Crawford, Kevin Benedict

News Feed Item

DEADLINE MONDAY: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Nu Skin Enterprises Inc. and a Lead Plaintiff Deadline of March 24, 2014

NEW YORK, March 21, 2014 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Utah on behalf of investors who purchased Nu Skin Enterprises Inc. ("Nu Skin" or the "Company") (NYSE: NUS) common stock between July 10, 2013 and January 14, 2014.

Protecting the Rights of Shareholders.

Click here to learn about the case: http://docs.wongesq.com/NUS-Info-Request-Form-147.  There is no cost or obligation to you.

The complaint alleges that the Company made materially false and/or misleading statements and omitted materially adverse facts regarding the Company's business, operations, and prospects. In particular, it is alleged that the Company engaged in fraudulent sales practices and failed to comply with China's laws and regulations.

If you suffered a loss in Nu Skin you have until March 24, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.  To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/NUS-Info-Request-Form-147.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:    
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

Logo - http://photos.prnewswire.com/prnh/20120409/MM84375LOGO

SOURCE The Law Offices of Vincent Wong

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.